Role of adjuvant chemotherapy in patients with stage II nonseminomatous germ-cell tumors.
Two options exist in the management of pathologic stage II nonseminomatous germ-cell tumors after retroperitoneal lymphadenectomy. First, patients may be followed closely and given three or four cycles of cisplatin-based chemotherapy at relapse. This option is appropriate only if compliance with follow-up is ensured. Second, patients with pathologic stage N2b or N3 disease may be given two cycles of cisplatin-based adjuvant chemotherapy. This approach nearly guarantees a cure but subjects patients who are not destined to have a relapse to chemotherapy. Such management is mandatory in patients who are noncompliant.
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
R J
RJ
Motzer
G J
GJ
Bosl
D017024:Chemotherapy, Adjuvant; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery